ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Historical Holders from Q4 2014 to Q4 2025

Type / Class
Equity / Common stock, par value $0.001 per share (the "Common Stock")
Symbol
ARWR on Nasdaq
Shares outstanding
138,764,349
Price per share
$66.39
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
110,885,706
Total reported value
$3,823,556,089
% of total 13F portfolios
0%
Share change
+5,231,497
Value change
+$261,985,934
Number of holders
297
Price from insider filings
$66.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% $253,631,486 19,012,855 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 11% $245,296,138 15,525,072 The Vanguard Group 30 Jun 2025
Avoro Capital Advisors LLC 8.3% -13% $193,377,834 -$8,581,554 11,517,441 -4.2% Avoro Capital Advisors LLC 30 Jun 2025
STATE STREET CORP 4.6% -10% $106,970,030 -$10,547,360 6,371,056 -9% STATE STREET CORPORATION 30 Jun 2025
As of 30 Sep 2025, ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR) has 297 institutional shareholders filing 13F forms. They hold 110,885,706 shares. of 138,764,349 outstanding shares (80%) .

Top 25 institutional shareholders own 67% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 20,224,825 +4.1% 0.01% $697,554,214
VANGUARD GROUP INC 12% 16,035,870 +3.3% 0.01% $553,077,156
Avoro Capital Advisors LLC 7.9% 10,900,000 +2.8% 4.9% $375,941,000
STATE STREET CORP 4.6% 6,397,364 +0.41% 0.01% $220,645,084
FMR LLC 4.2% 5,759,830 +11% 0.01% $198,656,549
Slate Path Capital LP 3.6% 4,982,000 -4.8% 2.7% $171,829,180
GEODE CAPITAL MANAGEMENT, LLC 2.3% 3,131,042 +5.1% 0.01% $108,008,198
Siren, L.L.C. 1.9% 2,669,880 0% 3.6% $92,084,161
Driehaus Capital Management LLC 1.5% 2,099,398 0.52% $72,408,237
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.5% 2,081,689 +3143% 0.05% $71,797,454
GOLDMAN SACHS GROUP INC 1.3% 1,773,878 -16% 0.01% $61,181,052
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 1.3% 1,759,489 -34% 0.01% $60,684,776
MORGAN STANLEY 1.2% 1,702,674 -0.15% 0% $58,725,264
BAKER BROS. ADVISORS LP 1.2% 1,670,762 +78% 0.42% $57,624,581
MARSHALL WACE, LLP 1% 1,436,840 -33% 0.05% $49,556,613
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.97% 1,345,860 +15% 0.01% $46,418,711
NORTHERN TRUST CORP 0.95% 1,311,590 +3.1% 0.01% $45,236,740
Fisher Asset Management, LLC 0.76% 1,053,794 +133% 0.01% $36,345,353
Woodline Partners LP 0.72% 1,000,158 +34% 0.16% $34,495,449
DEERFIELD MANAGEMENT COMPANY, L.P. 0.72% 993,000 0.52% $34,248,570
JANUS HENDERSON GROUP PLC 0.7% 973,567 +1853% 0.02% $33,534,515
UBS Group AG 0.66% 918,183 -43% 0.01% $31,668,132
Western Financial Corp/CA 0.59% 820,239 0% 12% $28,290,043
Bank of New York Mellon Corp 0.59% 814,548 -0.43% 0.01% $28,093,746
Balyasny Asset Management L.P. 0.57% 792,966 0.06% $27,349,397

Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 1,122,274 $74,630,139 +$18,103,279 $66.39 14
2025 Q3 110,885,706 $3,823,556,089 +$261,985,934 $34.49 297
2025 Q2 105,716,035 $1,671,181,802 +$44,748,514 $15.80 279
2025 Q1 103,362,113 $1,318,228,654 +$23,656,546 $12.74 258
2024 Q4 99,701,045 $1,874,384,692 +$32,738,534 $18.80 267
2024 Q3 97,715,477 $1,892,897,060 -$93,908,485 $19.37 267
2024 Q2 97,822,928 $2,542,052,894 +$57,202,679 $25.99 272
2024 Q1 96,658,787 $2,763,026,175 +$544,741,705 $28.60 267
2023 Q4 77,504,804 $2,371,960,338 +$86,943,186 $30.60 265
2023 Q3 74,643,254 $2,005,663,054 +$41,168,266 $26.87 253
2023 Q2 71,799,685 $2,559,646,627 -$10,508,327 $35.66 267
2023 Q1 72,976,301 $1,851,849,623 -$23,671,296 $25.40 250
2022 Q4 73,474,031 $2,977,955,799 +$97,292,640 $40.56 276
2022 Q3 71,284,086 $2,353,949,365 -$40,859,478 $33.05 264
2022 Q2 72,095,607 $2,538,257,759 +$100,531,936 $35.21 263
2022 Q1 69,254,530 $3,184,523,615 +$35,685,819 $45.99 294
2021 Q4 67,961,552 $4,505,834,422 +$55,872,415 $66.30 297
2021 Q3 66,549,683 $4,154,048,742 -$66,618,101 $62.43 282
2021 Q2 66,896,948 $5,539,659,575 -$140,144,186 $82.82 304
2021 Q1 68,464,454 $4,541,675,803 -$29,602,424 $66.31 281
2020 Q4 69,478,160 $5,331,874,119 +$80,806,659 $76.73 302
2020 Q3 68,146,322 $2,935,188,814 -$17,523,513 $43.06 252
2020 Q2 68,613,840 $2,962,938,209 +$129,556,464 $43.19 238
2020 Q1 65,790,124 $1,891,626,404 -$65,617,767 $28.77 228
2019 Q4 64,818,441 $4,111,036,094 -$251,364,075 $63.43 284
2019 Q3 65,607,783 $1,847,640,120 -$64,133,875 $28.18 215
2019 Q2 68,226,591 $1,809,138,980 +$469,493,968 $26.50 207
2019 Q1 58,944,394 $1,081,619,759 +$8,000,225 $18.35 172
2018 Q4 58,642,004 $728,108,442 +$2,744,915 $12.42 156
2018 Q3 55,874,420 $1,071,112,217 +$87,737,206 $19.17 131
2018 Q2 51,724,461 $703,394,391 +$174,211,743 $13.60 114
2018 Q1 40,751,284 $293,798,301 +$131,632,594 $7.21 88
2017 Q4 23,358,744 $85,959,545 +$30,381,058 $3.68 74
2017 Q3 15,003,494 $64,925,247 +$4,080,629 $4.33 54
2017 Q2 15,405,069 $24,955,147 -$15,547,121 $1.62 53
2017 Q1 24,329,456 $45,009,540 +$7,661,442 $1.85 78
2016 Q4 25,470,006 $39,473,542 -$54,918,365 $1.55 77
2016 Q3 30,122,030 $221,392,091 +$70,394,875 $7.35 94
2016 Q2 20,597,873 $109,582,112 +$97,619,255 $5.32 84
2016 Q1 2,128,149 $10,255,000 +$10,255,000 $4.82 6
2015 Q4 500 $4,000 $8.00 1
2015 Q3 500 $3,000 $6.00 1
2015 Q2 500 $4,000 $8.00 1
2015 Q1 500 $4,000 $8.00 1
2014 Q4 500 $4,000 $8.00 1